To ensure the enhanced degradation of the ABL1 protein was due to an on-target mechanism, we evaluated whether cancer-derived mutations, including Y87C, F102C, W131G, and F133V (Supplementary Fig. 4f)44, that abrogate SPOP binding to substrates would fail to promote ABL1 protein degradation. Here, ABL1 is linked to cancer.